Sector News

Novartis, Celgene meds take the biggest shares of cancer drug spending

May 28, 2015
Life sciences
Cancer drug spending is up. Cancer drug prices are way up. And as a new Express Scripts report shows, spending on each cancer patient is mounting; it’s among the reasons why a growing number of individual patients account for $100,000-plus in annual drug spending. And a few big drugs made big contributions to that rise.
 
As the American Society of Clinical Oncology meeting approaches, the pharmacy benefits manager released some numbers on cancer drug spending. The top line? Spending on cancer meds grew by more than one-fifth last year, with a 9% increase in use and almost 12% increase in prices.
 
Prime suspects for that increase? The leukemia treatment Gleevec, from Novartis, which boasts the biggest share of the market at 12.5%. Fellow blood cancer treatment Revlimid–the multiple myeloma therapy from Celgene–came in close behind with 10.8% of pharmacy benefit spending.
 
In third place by market share is Lupron Depot, the AbbVie med used to treat several conditions, including prostate cancer. And rounding out the top 5 were two newly generic chemotherapies, capecitabine, also sold by Roche under the brand name Xeloda; and temozolomide, the Merck & Co. pill Temodar that’s used to treat brain tumors.
 
And the growth shows no sign of slowing, the PBM said in a blog post, partly because of new meds coming to market–including Pfizer’s blockbuster-to-be breast cancer med Ibrance (palbociclib), Novartis’ myeloma med Farydak (panobinostat) and Eisai’s thyroid cancer treatment Lenvima (lenvatinib). Not to mention the PD-1/PD-L1 immunotherapies that are swiftly racking up data (and approvals) in multiple cancers, including Merck’s Keytruda and Bristol-Myers Squibb’s Opdivo.
 
“Express Scripts expects cancer medications will maintain their lead position as a major contributor to drug spending in the pharmacy benefit, due to the availability of new medications and increased survival requiring long-term use of expensive and complex treatment,” the PBM notes.
 
That’s why Express Scripts is so keen on negotiating discounts with drugmakers, including pay-for-performance deals that would peg prices to results. It’s also why Express Scripts is impatiently waiting for–and lobbying on the behalf of–biosimilar meds. The PBM says 11 biosimilars closest to FDA approval could save the healthcare system $250 billion over the next decade. That would include Roche’s Avastin (bevacizumab) and Herceptin (trastuzumab), two of the top-selling cancer meds on the planet.
 
By Tracy Staton
 

Related News

March 6, 2021

Takeda takes full control of drug for rare epilepsies

Life sciences

The deal inked with New York-based Ovid Therapeutics carries an almost $200 million upfront payment and could be worth as much as $856 million provided the medicine, known as soticlestat, hits certain milestones. 

March 6, 2021

Novartis signs Covid-19 vaccine manufacturing agreement with CureVac

Life sciences

Novartis has entered an initial agreement to manufacture the mRNA and bulk drug product for CureVac’s Covid-19 vaccine candidate, CVnCoV.

March 6, 2021

Disney teams with Philips to bring its characters to pediatric imaging

Life sciences

A whole new world: Philips and the Walt Disney Company will use animated shorts featuring some of Disney’s most famous characters in customized stories created with clinical guidance from Philips.

Send this to a friend